Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

In Brief: Global OTC market

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Global OTC market: Report by SelfMedication International, a unit of IMS/Nielsen, concludes that over 40% of the world OTC market is held by 10 consumer product firms. The top OTC company based on worldwide sales is American Home Products with 7% of OTC sales, followed by Johnson & Johnson, Warner Wellcome, Procter & Gamble, SmithKline Beecham, Bayer, Bristol-Myers Squibb, Ciba, Rhone-Poulenc Rorer and Schering-Plough. Global self-medication accounted for almost an 18% share of total drug sales, according to the report, and 30% of the world OTC market is in the U.S. The two OTC categories that have had the "most positive growth" in the U.S. are dietary supplements and diagnostic tests, up 16% and 13%, respectively...

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS084050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By